CRIS Current Research Information System

CASTAGNETTI, FAUSTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.324
AS - Asia 10.887
EU - Europa 7.563
SA - Sud America 634
AF - Africa 560
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 9
Totale 30.996
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.191
VN - Vietnam 2.911
SG - Singapore 2.883
CN - Cina 2.759
GB - Regno Unito 2.049
IT - Italia 1.133
DE - Germania 921
SE - Svezia 902
HK - Hong Kong 610
FR - Francia 506
IN - India 474
BR - Brasile 455
NL - Olanda 443
RU - Federazione Russa 405
KR - Corea 261
IE - Irlanda 255
UA - Ucraina 255
JP - Giappone 242
BD - Bangladesh 211
ZA - Sudafrica 173
EE - Estonia 136
FI - Finlandia 133
TG - Togo 124
CI - Costa d'Avorio 103
JO - Giordania 88
CH - Svizzera 86
CA - Canada 82
BG - Bulgaria 78
AR - Argentina 66
PH - Filippine 65
ID - Indonesia 62
NG - Nigeria 53
PL - Polonia 50
TH - Thailandia 48
AT - Austria 45
BE - Belgio 45
IQ - Iraq 39
TW - Taiwan 39
SC - Seychelles 37
TR - Turchia 37
EC - Ecuador 33
MX - Messico 32
IR - Iran 28
ES - Italia 26
GR - Grecia 23
CL - Cile 22
PK - Pakistan 22
AU - Australia 17
CO - Colombia 16
RO - Romania 15
UZ - Uzbekistan 15
MA - Marocco 14
SA - Arabia Saudita 14
VE - Venezuela 14
PY - Paraguay 13
AE - Emirati Arabi Uniti 12
ET - Etiopia 12
LB - Libano 12
MY - Malesia 12
KE - Kenya 10
IL - Israele 9
LT - Lituania 9
CZ - Repubblica Ceca 7
NP - Nepal 7
PE - Perù 7
EG - Egitto 6
TN - Tunisia 6
DK - Danimarca 5
GE - Georgia 5
JM - Giamaica 5
LY - Libia 5
PT - Portogallo 5
AL - Albania 4
DZ - Algeria 4
HN - Honduras 4
MD - Moldavia 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
TZ - Tanzania 4
UY - Uruguay 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BO - Bolivia 3
NO - Norvegia 3
RS - Serbia 3
SY - Repubblica araba siriana 3
XK - ???statistics.table.value.countryCode.XK??? 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
CR - Costa Rica 2
CY - Cipro 2
EU - Europa 2
GM - Gambi 2
GT - Guatemala 2
HR - Croazia 2
KZ - Kazakistan 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
OM - Oman 2
TT - Trinidad e Tobago 2
AO - Angola 1
Totale 30.970
Salva come PNG Salva come JPEG
Città #
Singapore 2.049
Southend 1.849
Ashburn 1.173
Fairfield 1.100
Chandler 869
San Jose 751
Ho Chi Minh City 630
Woodbridge 579
Hanoi 571
Hong Kong 567
Wilmington 556
Houston 534
Hefei 530
Seattle 514
Dong Ket 464
Beijing 403
Cambridge 393
Princeton 391
Ann Arbor 326
Boardman 262
Dublin 253
Santa Clara 239
Seoul 233
Lauterbourg 212
Tokyo 204
Nanjing 181
Bologna 177
New York 169
Westminster 158
Los Angeles 156
Padova 141
Dallas 133
Lomé 124
Jacksonville 123
Berlin 116
Helsinki 115
Abidjan 102
Buffalo 102
Milan 94
Da Nang 88
Amman 84
Haiphong 84
Jinan 82
Saint Petersburg 78
Sofia 78
Turin 76
Shenyang 75
Redondo Beach 74
Bern 73
Council Bluffs 70
San Diego 61
Changsha 60
Frankfurt am Main 59
São Paulo 59
Bengaluru 58
Nanchang 57
Shanghai 52
Falls Church 50
Rome 50
Abeokuta 49
Munich 49
Tianjin 49
Guangzhou 48
Hebei 48
Brussels 44
Medford 44
Jiaxing 41
Warsaw 41
Jakarta 38
Phoenix 38
Orem 37
Hangzhou 36
Zhengzhou 35
Biên Hòa 34
Bremen 33
Des Moines 32
Florence 32
Nuremberg 32
Mülheim 31
Chicago 30
Redmond 30
Can Tho 29
Falkenstein 29
Norwalk 29
Hải Dương 27
London 26
Montreal 26
Brooklyn 24
Chengdu 24
Ningbo 24
The Dalles 23
Dearborn 22
Taizhou 22
Wuhan 22
Bangkok 21
Yubileyny 21
Atlanta 20
Baghdad 20
Mountain View 20
Paris 20
Totale 20.211
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 389
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia 386
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 355
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 307
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 299
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 280
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 276
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 275
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 267
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 255
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 253
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 243
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 234
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 232
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib 230
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients 229
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 228
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 228
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 220
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 220
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 220
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 214
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 213
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia 209
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 208
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 204
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 203
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 199
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 198
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 197
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 191
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 190
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 189
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 189
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 188
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 187
The EUTOS population-based registry: Incidence and clinical characteristics of 2904 CML patients in 20 European Countries 186
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 185
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 184
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 184
Immune dysregulation associated with co-occurring germline CBL and SH2B3 variants 183
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report 182
Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance/intolerance to imatinib. 182
A review of the European LeukemiaNet recommendations for the management of CML 180
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 176
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 175
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 175
Successful treatment of bilateral endogenous Fusarium solani endophthalmitis in a patient with acute lymphocytic leukaemia 175
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457 173
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 173
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 172
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 171
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 170
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 170
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 169
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia 168
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 168
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 167
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study 165
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 165
Leucemia mieloide cronica: terapia molecolare 164
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 164
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 164
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 163
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 162
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 161
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 161
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 161
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 160
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 159
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 159
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 159
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 159
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 159
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 157
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 156
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 156
DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia 154
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study 153
One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study 153
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 153
Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 153
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 153
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables 152
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. 152
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 152
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 152
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 150
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. 150
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. 150
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 150
INTERMITTENT IMATINIB (INTERIM) TREATMENT IN PH+-CML ELDERLY PATIENTS IN STABLE COMPLETE CYTOGENETIC RESPONSE 148
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 147
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 147
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 146
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights 145
Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom? 145
IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. 145
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 145
Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients 143
Totale 18.965
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.359
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.359
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021809 0 0 0 0 0 0 0 0 0 0 0 809
2021/20223.217 305 86 239 290 326 198 59 218 159 223 526 588
2022/20233.603 412 564 195 432 260 261 143 190 586 98 303 159
2023/20241.052 47 153 62 101 77 260 66 61 42 65 63 55
2024/20254.376 116 692 381 312 519 219 272 108 46 536 267 908
2025/202610.594 1.045 1.070 1.005 740 1.091 505 916 511 1.977 902 524 308
Totale 31.633